

**"CURRENT TRENDS IN THE ANALYSIS AND BIOANALYSIS OF
GLIMEPIRIDE: AN IN-DEPTH REVIEW"****Ritika Shrivastava*, Aakankha Sinha and Dr. S. J. Daharwal**

University Institute of Pharmacy, Pt. Ravishanker Shukla University, Raipur (C.G.) 492001, India.

Article Received on
12 March 2025,Revised on 01 April 2025,
Accepted on 20 April 2025

DOI: 10.20959/wjpps20255-29699

***Corresponding Author****Ritika Shrivastava**University Institute of
Pharmacy, Pt. Ravishanker
Shukla University, Raipur
(C.G.) 492001, India.**ABSTRACT**

Glimepiride is a sulfonylurea family antidiabetic drug that is mostly administered to treat type 2 diabetes. The current study's primary focus is on the advancement of analytical methods and the many strategies currently employed for aspirin estimation, whether in pharmaceutical dose form or bulk. Because analytical processes enable us to get both qualitative and quantitative data utilizing the most up-to-date analytical equipment, they are essential for determining compositions. Glimepiride can be analyzed using spectroscopy, electrochemistry, chromatography, and other techniques. These techniques help to understand critical process elements and lessen the negative impact they have on precision and accuracy. To satisfy legal criteria and uphold strict standards for the caliber of commercial items, analytical methods must be developed. Following the reference, regulatory

agencies in several countries have created policies and processes for authorizing, verifying, and registering.

KEYWORDS: Glimepiride, UV – spectroscopy, HPTLC, HPLC.**INTRODUCTION**

Glimepiride is a N-acylurea, N-sulfonylurea, and sulfonamide class of drug. Glimepiride is a second-generation sulfonylurea that received FDA approval in 1995 to use for the improvement of glycemic control in adults with type 2 diabetes mellitus. Because of metformin's proven safety and effectiveness, it is considered a second-line choice. It is advised that glimepiride be used in conjunction with dietary and activity changes. When taken orally, its effects peak in three hours and last for roughly a day.^[1]

Physicochemical properties

It appears as white solid form of powder. Its molecular weight is 490.62g/mol. It is the BCS class 2 drug, has solubility in DMSO and is poorly water soluble. Its melting point is 212.2-214.5 °C. Its pKa is 4.32.^[2]




Figure 1: Chemical structure of Glimepiride.

Pharmacokinetics

Glimepiride has a linear pharmacokinetic profile and is fully absorbed when taken orally within an hour of dosing. After two to three hours, the peak plasma concentrations (C_{max}) were attained. Glimepiride has a plasma protein binding rate of over 99.5%. The CYP2C9 enzyme mediates the oxidative biotransformation of glimepiride, resulting in the creation of a pharmacologically active main metabolite known as cyclohexyl hydroxymethyl derivative (M1). One or more cytosolic enzymes can further break down M1 into the inactive metabolite carboxyl derivative (M2). Glimepiride has an elimination half-life of roughly five to eight hours.^[3]

Pharmacodynamics

Glimepiride increases peripheral glucose uptake by stimulating the release of insulin granules from the pancreatic beta cells and improving peripheral tissue sensitivity to insulin, which lowers plasma blood glucose and glycated hemoglobin (HbA1C) levels.^[4]

Mechanism of action

In order to increase insulin secretion from the beta cell, glimepiride binds non-specifically to the B sites of the sulfonylurea receptor-1 (SUR1) and sulfonylurea receptor-2A (SUR2A) subunits as well as the A site of the SUR1 subunit of the channel, blocking the ATP-sensitive potassium channel.^[5]

Need of analytical method development

Quality control labs use analytical techniques to evaluate the efficacy, safety, purity, performance, and identification of pharmaceutical products. The ICH has published analytical guidance documents on stability testing (Q1), analytical technique validation (Q2), contaminants in drug substances and products (Q3), and specifications for new drug substances and products (Q6). The analytical methods used in manufacturing are among the most important to regulatory bodies. The pharmaceutical must be approved by regulatory bodies once the applicant demonstrates control over the entire drug development process using recognized analytical methods.^[6]

Analytical method development by UV-visible spectroscopy

The study of how electromagnetic energy interacts with materials in the ultraviolet-visible range is known as ultraviolet-visible spectroscopy. Wavelengths in the ultraviolet (UV) vary from 200 to 400 nm. Its foundation is the Beer-Lambert law, which asserts that a solution's absorbance and route length are directly proportional. For a given route length, it can thus be used to calculate the absorber's concentration in a solution. It is crucial to understand how quickly absorbance varies with concentration.^[7]

Table 1: Analytical method development by UV – visible spectroscopy.

S. No.	Sample	Method/Instrument model	Solvent/ Solution	Wavelength (nm)	Reference
1.	Tablet and bulk	UV-Visible Spectrophotometer 2501 PC (Double Beam) of Shimadzu	Methanol	227.6	[8]
2.	Tablet	Shimadzu UV-Visible double beam spectrophotometer (Shimadzu, Japan)	Sodium hydroxide	235, 233, and 237	[9]
3.	Tablet and bulk	UV-Visible Spectrophotometer (Elico SL-150 model of Elico Pvt. Ltd, India)	Cresol Red dye (Method A) and Bromophenol Blue dye (Method B) in methanol and chloroform	450 and 578 for methods A and B.	[10]
4.	Tablet	Labindia 3000+ UV-Visible Spectrophotometer	Methanol	225	[11]
5.	Tablet and bulk	Elico model SL 159 UV-Visible Single beam spectrophotometer	Methanol	228	[12]
6.	Tablet and bulk	Shimadzu UV-1800 spectrophotometer	Methanol	218	[13]
7.	Tablet	Double - beam Shimadzu (Kyoto, Japan) UV – Visible spectrophotometer, Model UV- 1601 PC	Methanol	231	[14]
8.	Tablet and bulk	UV-Visible double beam spectrophotometer (Shimadzu-1800 Japan)	Methanol	227	[15]

Analytical method development by HPLC

The most used separation method and one of the most reputable analytical procedures is high performance liquid chromatography (HPLC). For over 40 years, it has been utilized in labs all over the world for a number of applications, such as synthetic chemistry, clinical chemistry, pharmaceutical sciences, food and environmental evaluations, etc. A liquid or a solid could serve as the stationary phase in this procedure. The components of a combination can be separated using HPLC and a liquid mobile phase. A form of liquid chromatography known as "high-performance liquid chromatography" (HPLC) involves physically pumping the liquid mobile phase through a stationary phase-containing column. The core of HPLC systems is the column. Accurate certification requires a consistent and symmetrical peak, which is produced by a proper silica and bonding procedure. The RP columns C18 (USP L1), C8 (USPL8), Phenyl (USP L11), and Cyno (USP L18) are frequently used.^[16]

Table 2: Analytical method development by HPLC.

S. No.	Sample	Stationary phase/ column	Mobile phase	Wavelength (nm)	Flow rate (ml/min)	RT (min)	Reference
1.	Tablet	C-18 column (20mm×4mm)	0.023M Potassium dihydrogen phosphate buffer (pH6.0) and acetonitrile in ratio of 60:40v/v	230	1.0	4.5	[17]
2.	Tablet	LC-18column (25 cm × 4 mm × 5 μm)	Acetonitrile, methanol and phosphate buffer, pH 3.5 in the ratio of 20:50:30 (v/v/v)	220	1.0	12.189	[18]
3.	Tablet	C-18 column (250 x 4.6 mm, particle size 5μm)	Acetonitrile: 0.1% Formic acid in ratio (55:45 v/v)	250	1.0	-	[19]
4.	Tablet and bulk	C- 18 column (250 mm X 4.6 0mm, particle size 5μm)	methanol and 0.5 percent potassium dihydrogen phosphate (pH 4) in ratio 74:26	210	1.0	-	[20]
5.	Tablet and bulk	C18 column 150 × 4.6 mm, with 5 μm particle size	Monobasic sodium phosphate and acetonitrile	228	1.0	9.30	[21]
6.	Tablet and bulk	C-8 column (250 × 4.6 mm, particle size 5-μm)	Acetonitrile: phosphate buffer (60: 40 (v/v), pH 3.0)	235	1.0	9.39	[22]
7.	Tablet and bulk	C18, 250mm X 4.6mm, particle size 5 μm	70% Methanol and 30 % HPLC water	229	0.85	6.8	[23]
8.	Tablet	C 18 column (125 x 4 mm, particle size 5μm)	Acetonitrile, water and glacial acetic acid (550:450:0.6 v/v)	230	1.0	-	[24]
9.	Tablet and bulk	ODS 3V (150 × 4.6 mm, i.e. 5 μm)	0.02 M Phosphate buffer, pH 2.5 (solvent A) and acetonitrile (solvent B)	230	1.0	11.708	[25]
10.	Tablet and bulk	ODS (250 × 4.6 mm, 5μm)	Acetonitrile and ammonium acetate (pH 4.5; 20mM) in ratio 60:40 (v/v)	230	1.0	10.2	[26]
11.	Tablet	C-18 250 × 4.60 mm, 5 μm	Methanol–phosphate buffer (pH 4.3) in ratio 75:25 v/v	258	1.0	10.17	[27]

12.	Tablet	C18 (250×4.6 mm, 5.0 μm)	Potassium phosphate buffer (pH 6.5) -methanol in ratio (34: 66, v/v)	228	1.0	-	[28]
13.	Tablet	C8 column (5μm, 2.50 x 4.60 mm)	Methanol: 0.025M potassium dihydrogen phosphate (pH 3.20) in ratio (70: 30, v/v)	235	1.0	6.0	[29]
14.	Tablet and bulk	ODS-3V (250 mm × 4.6 mm, 5 μm)	Phosphate buffer (pH 5), acetonitrile, tetrahydrofuran (40: 50: 10)	228	1.7	5.0	[30]
15.	Tablet	Cyano, 250 x 4.6mm, 5.0	Acetonitrile and water (4:1, v/v)	230	0.8	38.73	[31]
16.	Tablet	SIL (250 mm × 4.6 mm i.d. 5 μm)	Aqueous phase (20 mM phosphate buffer, adjusted to pH 3.0) and an organic phase (methanol:acetonitrile; 62.5:37.5) in the ratio of 80:20	230	1.0	5.87	[32]

Analytical method development by HPTLC

The potent analytical technique known as HPTLC is very beneficial for both qualitative and quantitative jobs. Separation may result by partitioning, adsorption, or both, depending on the type of adsorbents applied to the plates and the development solvent solution. Principle, theory, instrumentation, implementation, optimisation, validation, automation, and qualitative and quantitative analysis are just a few of the several facets that make up HPTLC foundations.^[33]

Table 3: Analytical method development by HPTLC.

S. No.	Sample	Stationary phase/ column	Mobile phase	Wavelength (nm)	Reference
1.	Tablet and bulk	Silica gel 60 F254	Chloroform: methanol: Ammonia (9:1.5:0.2 v/v/v)	238	[34]
2.	Tablet	Silica gel 60 F254	Ethyl acetate, benzene, and hexane (4:3:1 v/v/v)	238	[35]

Bioanalytical method development

Bioanalysis is a key component of medication development. These days, bioanalysis is essential to toxicological evaluation, pharmacokinetic and pharmacodynamic research, and drug development. The creation of bioanalytical techniques is one of the drug development hurdles. The quantitative identification of various analyte types in biological matrices also requires the validation of bioanalytical techniques. The steps in the bioanalysis process include sampling, sample preparation, analysis, calibration, data review, and reporting.^[36]

Table 4: Bioanalytical Method Development.

S. No.	Method	Sample	Stationary phase/column	Mobile phase	Wavelength (nm)	Flow rate (ml/min)	RT (min)	Reference
1.	HPLC	Tablet and human plasma	C18 column (150 × 4.6 mm, 5 µm)	0.05% Triethylamine (pH-3.5), acetonitrile and methanol in the ratio of 55:15:30	248	1.0	-	[37]
2.	HPLC	Bulk and rat plasma	C18 stationary phase (250 x 4.6 mm, 5 µm)	Methanol: water (85:15 v/v)	230	1.0	2.5	[38]
3.	UPLC	Bulk powder, tablets and spiked human plasma	1.7µ C18 100A (2.1-mm × 50-mm)	0.05 M Potassium dihydrogen phosphate buffer pH 5.00 (A) with 0.10M sodium dodecyl sulfate and isopropanol (15.00-25.00%) (B)	230	0.20	-	[39]
4.	LC-UV	Bulk and human plasma	RP 18e, (125 X 4, 5 µm)	Phosphate buffer (50 mM) with octane sulfonic acid (10 mM), methanol and acetonitrile as a mobile phase (55:10:35, v/v)	228	1.0	6.4	[40]
5.	UPLC	Tablet and human plasma	1.7 µm XB-C18 100 Å (50×2.1 mm) column	(85:15 v/v). Solvent A: mixture of [0.1 M SDS- 0.3% triethyl amine- 0.1% phosphoric acid (pH 6)]. Solvent B: n-propanol.	225	0.2	-	[41]

CONCLUSION

This study's main focus has been on the various analytical methods used to determine how much glimepiride is present in various prescriptions and in the bulk form of those medications. There are numerous dose formulas for glimepiride. The researchers have worked to create analytical methods such as UV spectrophotometry, TLC, RP-HPLC, HPLC, HPTLC, and others. Every analytical method developed has a higher sample throughput, is automated, highly sensitive, reproducible, and accurate. The literature survey's objective is to compile information on different analytical instrumental methodologies. A new analytical method could be developed with the help of such information.

Conflicting interests

In this paper, the author disclosed no conflicts of interest.

REFERENCE

1. Davis SN. The role of glimepiride in the effective management of Type 2 diabetes, 2004; 18: 367–76.

2. Saara A, Gopal K, Karthick S, Ashi A, Karthickeyan K. A Review on Glimepiride vs Teneligliptin as a Second-Line Drug for the Treatment of Type 2 Diabetes Mellitus.
3. Niemi M, Cascorbi I, Timm R. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes, 2002; 450: 326–32.
4. Briscoe VJ, Griffith ML, Davis SN. The role of glimepiride in the treatment of type 2 diabetes mellitus, 2010; 225–35.
5. Müller G. The Mode of Action of the Antidiabetic Drug Glimepiride-Beyond Insulin Secretion, 2005; 499–518.
6. Lavanya G, Sunil M, Eswarudu M., Eswaraiah MC, Harisudha K, Spandana BN. ANALYTICAL METHOD VALIDATION: AN UPDATED REVIEW Department of Pharmaceutical Analysis, Anurag Pharmacy College, Ananthagiri (V), Kodad (M)-508206, Nalgonda (Dt),. Int J Pharm Sci Res., 2013; 4(4): 1280–6.
7. Bharti Mittu AC, Chauhan P. Analytical Method Development and Validation: A Concise Review. J Anal Bioanal Tech., 2015; 06(01): 1–5.
8. Kharat AR, Pakhare MK, Kharat KR. STABILITY INDICATING UV SPECTROPHOTOMETRIC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE IN BULK DRUG AND, 2024; 17(3): 1362–70.
9. Džambić LA, Gjuraj M, Dacić M, Hukić M. UV VIS method of estimation for Glimepiride in Tablets, 2023; 8(6): 1–4.
10. Study about Nano Polyphenol : Biomaterial in Functional Food and Its Preparation. 2021.
11. Pradesh A. Development and Validation of A Spectrophotometric Method for Quantification and Dissolution Studies of Glimepiride in Tablets, 2012; 9(2): 993–8.
12. Adithya BP, Vijayalakshmi M, Krishna UVR, Reddy KN. Stability Indicating Spectrophotometric Method for the Estimation of Glimepiride in Bulk and Various Marketed Brands of Tablets, 2012; 2012(4): 1–5.
13. Kande T, Dhekale P, Khatal S, Borude P. Development and Validation of Analytical Methods for Simultaneous Spectrophotometric Determination of Pioglitazone and Glimepiride by Derivative Method, 2019; 4(1): 822–5.
14. Afroz A, Haque T, Talukder MU, Islam SMA. Spectrophotometric Estimation of Rosuvastatin Calcium and Glimepiride in Tablet Dosage Form Spectrophotometric Estimation of Rosuvastatin Calcium and Glimepiride in Tablet Dosage Form. 2014; (January 2011).
15. Patel D. Development and Validation of UV Spectrophotometric methods for

- simultaneous estimation of Lobeglitazone Sulfate and Glimepiride in combined dosage form, 2024; (June): 62–9.
16. Sanjay KD, Kumar HD. Importance of RP-HPLC in analytical method development: A review. *Int J Pharm Sci Res.*, 2012; 3(12): 4626–33.
 17. Patle D. Stability indicating gradient liquid chromatographic technique for the simultaneous estimation of rosiglitazone, glimepiride and metformin HCl in pharmaceutical dosage forms, 2023; 10(3): 190–6.
 18. Aljaberi A, Shahin A, Albals D, Mohammad B, Abu-samak M. DEVELOPMENT AND VALIDATION OF A NOVEL STABILITY- INDICATING RP-HPLC METHOD FOR THE SIMULTANEOUS QUANTITATION OF AMLODIPINE, GLIMEPIRIDE AND, 2024; 72.
 19. Jagadeesh M, Nehru J, Housing K, Colony B, Akshita GL, Arcade L, et al. METHOD DEVELOPMENT AND METHOD VALIDATION OF GLIMEPIRIDE IN FORMULATION BY HPLC IN REVERSE PHASE, 2023; 8(4): 22–6.
 20. Gubbiyappa KS. Method development and validation of metformin hcl , ramipril , atorvastatin and glimepiride by rp – hplc in bulk and tablet dosage form, 2023; (December 2022).
 21. Kumar A, Sharma AK, Dutt R. Reverse-Phase High-Performance Liquid Chromatography Method Development and Validation for Estimation of Glimepiride in Bulk and Tablet Dosage Form, 2020.
 22. Ramesh D, Habibuddin M. Stability Indicating RP-HPLC Method for the Simultaneous Determination of Atorvastatin Calcium, Metformin Hydrochloride, and Glimepiride in Bulk and Combined Tablet Dosage Form. 2014; 2014.
 23. Shaikh SS, Sciences P, Rajasthan A. Simultaneous estimation of pioglitazone, glimepiride & metformin hydrochloride in bulk & tablet dosage form by UV, RP-HPLC method SIMULTANEOUS ESTIMATION OF PIOGLITAZONE, GLIMEPIRIDE & METFORMIN HYDROCHLORIDE IN BULK & TABLET DOSAGE FORM BY UV, RP-HPL. 2022; (November).
 24. Validation M, Maslarska V. Vania Maslarska, 2014; 5(8): 3195–8.
 25. Neelima K, Prasad YR. Analytical Method Development and Validation of Metformin, Voglibose, Glimepiride in Bulk and Combined Tablet Dosage Form by Gradient RP-HPLC. 27–33.
 26. Arumugam K, Therapeutics A, Ganesan S, Rao CM, Musmade PB. Simultaneous determination of pioglitazone and glimepiride in bulk drug and pharmaceutical dosage

- form by RP-HPLC method SIMULTANEOUS DETERMINATION OF PIOGLITAZONE AND GLIMEPIRIDE IN BULK DRUG AND PHARMACEUTICAL DOSAGE FORM BY RP-HPLC METHOD, 2008; (November).
27. Jain D, Jain S, Jain D, Amin M. Simultaneous Estimation of Metformin Hydrochloride, Pioglitazone Hydrochloride, and Glimepiride by RP-HPLC in Tablet Formulation, 2008; 46(July): 501–4.
 28. Paulista UE, Alfenas UF De. Multivariate Development and Validation of a Stability-Indicating HPLC Method for the Determination of Glimepiride in Tablets. 2013; 960–7.
 29. Sebaiy MM, El-adl SM, Baraka MM, Hassan AA. Rapid RP-HPLC Method for Simultaneous Estimation of Some Antidiabetics; Metformin, Gliclazide and Glimepiride in Tablets, 2019; 62(3): 429–40.
 30. Journal of Chemistry - 2012 - Nirupa - RP-HPLC Analytical Method Development and Validation for Simultaneous Estimation of.pdf.
 31. Navaneethan G, Karunakaran K, Elango KP. SIMULTANEOUS ESTIMATION OF PIOGLITAZONE, GLIMEPIRIDE AND GLIMEPIRIDE IMPURITIES IN COMBINATION DRUG PRODUCT BY A VALIDATED STABILITY- INDICATING RP-HPLC METHOD, 2011; 3: 1–4.
 32. Vaingankar PN, Amin PD. Development and Validation of Stability-Indicating RP-HPLC Method for Simultaneous Determination of Metformin HCl and Glimepiride in Fixed-Dose Combination, 2016; 13–20.
 33. Rashmin P, Mrunali P, Nitin D, Nidhi D, Bharat P. HPTLC method development and validation: Strategy to minimize methodological failures. J Food Drug Anal, 2012; 20(4).
 34. Patwari A, Desai U, Suhagia B. Dual run-dual wavelength HPTLC method development and validation for determination of five Antidiabetic drugs in bulk and their pharmaceutical dosage forms. Int J Pharm Pharm Sci., 2013; 5(SUPPL 3): 254–8.
 35. Sen AK, Sarkar T, Sen DB, Maheshwari RA, Zanzwar AS, Dumpala RL. Quantitative determination of lobeglitazone sulfate and glimepiride in combined tablet by robust high-performance thin layer chromatographic method. Sep Sci Plus, 2024; 7(7): 1–12.
 36. Moein MM, El Beqqali A, Abdel-Rehim M. Bioanalytical method development and validation: Critical concepts and strategies. J Chromatogr B Anal Technol Biomed Life Sci [Internet]. 2017; 1043: 3–11. Available from: <http://dx.doi.org/10.1016/j.jchromb.2016.09.028>
 37. Lakshmi KS, Rajesh T. Iranian Chemical Society Development and Validation of RP-HPLC Method for Simultaneous Determination of Glipizide, Rosiglitazone, Pioglitazone,

- Glibenclamide and Glimepiride in Pharmaceutical Dosage Forms and Human Plasma., 2011; 8(1): 31–7.
38. Dewani AP, Researcher I, Chandewar A V. Approaches Development and Validation of RP-HPLC Method for Estimation of Glimepiride in Rat Plasma-Application to Pharmacokinetic Studies, 2016;(December).
39. Fouad MM, Rashed NS, Hosameldin AI. Eco-friendly micellar ultra-performance liquid chromatography (UPLC) method for simultaneous determination of non-communicable diseases drugs in bulk powder, spiked human plasma and in individual dosage forms, 2024; 7: 60–9.
40. Jingar JN, Rajput SJ, Dasandi B, Rathnam S. Development and Validation of LC-UV for Simultaneous Estimation of Rosiglitazone and Glimepride in Human Plasma, 2008; (11): 951–5.
41. Elmasry MS, Hassan WS, Merey HA, Nour IM. Earth-friendly micellar UPLC technique for determination of four hypoglycemic drugs in different pharmaceutical dosage forms and spiked human plasma, 2023; 1–11.